Eyepoint Pharmaceuticals Inc (EYPT)

$17.08 -0.74 (-4.15%)
Market Cap 1.47B
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,429,818
Avg Vol 1,347,702
Day's Range N/A - N/A
Shares Out 82.79M
Stochastic %K 98%
Beta 1.67
Analysts Strong Sell
Price Target $34.00

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Address:
480 Pleasant Street, Suite C-400, Watertown, United States
Novellino
Novellino Aug. 19 at 12:20 PM
$EYPT
0 · Reply
XRProcketman
XRProcketman Aug. 19 at 11:46 AM
$EYPT
0 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 19 at 11:39 AM
$MRNA up over 60% pharmas moving $MRK 10% $EYPT RECOVERING C/0 buying $TENX bunch of sc 13g over 22 million with 37 million outstanding $KPTI still august submission of sdna is this month
1 · Reply
MesserschmittBavaria
MesserschmittBavaria Aug. 19 at 11:38 AM
$EYPT 6-8$ soon and waiting for news
0 · Reply
Novellino
Novellino Aug. 19 at 11:29 AM
$EYPT It is a gamble, as always, but Duvaryu has proven effective—currently the specific drug with the most potential—and an acquisition by Big Pharma cannot be ruled out.
0 · Reply
Hass19
Hass19 Aug. 19 at 11:25 AM
$EYPT $6+ by the end of the day today
1 · Reply
BrexitIsStupid
BrexitIsStupid Aug. 19 at 11:11 AM
$EYPT It has recovered better than I thought it would. I am still down a lot but less worried now. As long to we get a positive Phase III result in Q4, I think the story and success continues.
0 · Reply
Love_whams
Love_whams Aug. 19 at 10:13 AM
$EYPT moving nicely my main watch included $ANNA debt free & cash rich ! gas prices TTF surging away ! & $GDC is the lotto ticket play 7500 $BTC.X just confirmed in Q10 report market cap is 50x lower than it should be watch this space save this post IMO NFA all 3 will BOOM
0 · Reply
ArmyGreen4Runner
ArmyGreen4Runner Aug. 19 at 9:47 AM
$EYPT $6-$7 by EOD
1 · Reply
Jiggles
Jiggles Aug. 19 at 9:35 AM
$EYPT
0 · Reply
Latest News on EYPT
EyePoint price target lowered to $20 from $43 at Jones

2026-08-19T08:25:22.000Z - 4 hours ago

EyePoint price target lowered to $20 from $43 at Jones

EyePoint downgraded to Neutral from Buy at Chardan

2026-08-18T12:05:57.000Z - 1 day ago

EyePoint downgraded to Neutral from Buy at Chardan

EyePoint downgraded to Neutral from Buy at H.C. Wainwright

2026-08-18T10:10:15.000Z - 1 day ago

EyePoint downgraded to Neutral from Buy at H.C. Wainwright

EyePoint price target lowered to $17 from $35 at Citi

2026-08-18T10:00:23.000Z - 1 day ago

EyePoint price target lowered to $17 from $35 at Citi

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

2026-08-18T08:35:11.000Z - 1 day ago

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

2026-08-18T00:55:19.000Z - 1 day ago

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

Clear Street sees less competition for Ocular after EyePoint miss

2026-08-17T20:25:34.000Z - 1 day ago

Clear Street sees less competition for Ocular after EyePoint miss

OCUL

Laidlaw trims EyePoint target, still sees high chance of approval

2026-08-17T19:45:07.000Z - 1 day ago

Laidlaw trims EyePoint target, still sees high chance of approval

Laidlaw trims EyePoint target, still sees high change of approval

2026-08-17T19:40:14.000Z - 1 day ago

Laidlaw trims EyePoint target, still sees high change of approval

B. Riley views EyePoint study miss as positive for 4D Molecular

2026-08-17T18:15:14.000Z - 1 day ago

B. Riley views EyePoint study miss as positive for 4D Molecular

FDMT

EyePoint price target lowered to $8 from $30 at Jefferies

2026-08-17T16:40:40.000Z - 1 day ago

EyePoint price target lowered to $8 from $30 at Jefferies

Why Is EyePoint Pharmaceuticals (EYPT) Stock Down 69% Today?

2026-08-17T16:32:24.000Z - 1 day ago

Why Is EyePoint Pharmaceuticals (EYPT) Stock Down 69% Today?

EyePoint downgraded to Neutral from Overweight at JPMorgan

2026-08-17T15:55:07.000Z - 1 day ago

EyePoint downgraded to Neutral from Overweight at JPMorgan

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.

Aug 17, 2026, 11:14 AM EDT - 1 day ago

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.

EyePoint downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-08-17T13:30:09.000Z - 1 day ago

EyePoint downgraded to Neutral from Overweight at Cantor Fitzgerald

Morning Movers: EyePoint plummets following LUGANO trial results

2026-08-17T13:00:45.000Z - 1 day ago

Morning Movers: EyePoint plummets following LUGANO trial results

BABA CRGO HTHT LHX MU SNDK SOFI

EyePoint down 69% at $4.52 as Duravyu phase 3 study endpoint was not met

2026-08-17T12:45:37.000Z - 1 day ago

EyePoint down 69% at $4.52 as Duravyu phase 3 study endpoint was not met

EyePoint Transcript: Study result

Aug 17, 2026, 8:00 AM EDT - 2 days ago

EyePoint Transcript: Study result

EyePoint Press release: Study result

Aug 17, 2026, 8:00 AM EDT - 2 days ago

EyePoint Press release: Study result

EyePoint Slides: Study result

Aug 17, 2026, 8:00 AM EDT - 2 days ago

EyePoint Slides: Study result

EyePoint announces topline results from LUGANO trial

2026-08-17T11:25:39.000Z - 2 days ago

EyePoint announces topline results from LUGANO trial

EyePoint's eye drug misses main goal in late-stage trial

Aug 17, 2026, 7:16 AM EDT - 2 days ago

EyePoint's eye drug misses main goal in late-stage trial

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

Aug 17, 2026, 7:00 AM EDT - 2 days ago

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 14, 2026, 4:32 PM EDT - 4 days ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint price target raised to $55 from $47 at Cantor Fitzgerald

2026-08-06T12:17:08.000Z - 13 days ago

EyePoint price target raised to $55 from $47 at Cantor Fitzgerald

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Aug 5, 2026, 7:00 AM EDT - 14 days ago

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

EyePoint Earnings release: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 14 days ago

EyePoint Earnings release: Q2 2026

EyePoint Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 14 days ago

EyePoint Quarterly report: Q2 2026

EyePoint Slides: Investor presentation

Aug 4, 2026, 9:00 AM EDT - 14 days ago

EyePoint Slides: Investor presentation

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

Jul 30, 2026, 7:00 AM EDT - 20 days ago

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

EyePoint Appoints Tarek S. Hassan, M.D.

Jul 13, 2026, 7:00 AM EDT - 5 weeks ago

EyePoint Appoints Tarek S. Hassan, M.D.

Robinhood and 4 More Stocks That Were Just Added to This Firm's ‘Top Picks' List

Jul 2, 2026, 8:20 AM EDT - 6 weeks ago

Robinhood and 4 More Stocks That Were Just Added to This Firm's ‘Top Picks' List

HOOD EHC ERAS MU ORCL

EyePoint Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:20 AM EDT - 2 months ago

EyePoint Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

EyePoint Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:55 PM EDT - 2 months ago

EyePoint Transcript: Jefferies Global Healthcare Conference 2026

EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 9:00 AM EDT - 3 months ago

EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum

EyePoint Announces Participation at Upcoming Investor Conferences

May 19, 2026, 7:00 AM EDT - 3 months ago

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint's late-stage eye drug trials to continue after safety panel review

May 14, 2026, 9:51 AM EDT - 3 months ago

EyePoint's late-stage eye drug trials to continue after safety panel review

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

May 14, 2026, 7:00 AM EDT - 3 months ago

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

EyePoint Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

EyePoint Earnings Call Transcript: Q1 2026

EyePoint Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

EyePoint Earnings release: Q1 2026

EyePoint Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

EyePoint Quarterly report: Q1 2026

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

May 6, 2026, 7:00 AM EDT - 3 months ago

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 29, 2026, 7:00 AM EDT - 4 months ago

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

EyePoint Proxy statement: Proxy filing

EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

EyePoint Proxy statement: Proxy filing

EyePoint Slides: Investor presentation

Apr 23, 2026, 7:00 AM EDT - 4 months ago

EyePoint Slides: Investor presentation

EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Mar 25, 2026, 8:45 AM EDT - 5 months ago

EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Mar 20, 2026, 5:24 PM EDT - 5 months ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

OCUL

EyePoint Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

EyePoint Earnings Call Transcript: Q4 2025

EyePoint Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

EyePoint Annual report: Q4 2025

EyePoint Earnings release: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

EyePoint Earnings release: Q4 2025

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

Mar 4, 2026, 7:00 AM EST - 6 months ago

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 2:30 PM EST - 6 months ago

EyePoint Transcript: TD Cowen 46th Annual Health Care Conference

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

Mar 2, 2026, 7:00 AM EST - 6 months ago

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

EyePoint Slides: Investor presentation

Mar 2, 2026, 7:00 AM EST - 6 months ago

EyePoint Slides: Investor presentation

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

Feb 25, 2026, 7:00 AM EST - 6 months ago

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 18, 2026, 7:00 AM EST - 6 months ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer

EyePoint Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 11:00 AM EST - 6 months ago

EyePoint Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 6 months ago

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 7 months ago

EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference

EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 7 months ago

EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference

EyePoint Slides: Investor presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

EyePoint Slides: Investor presentation

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Jan 7, 2026, 7:00 AM EST - 8 months ago

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 7:00 AM EST - 8 months ago

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Nov 19, 2025, 7:00 AM EST - 9 months ago

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 9 months ago

EyePoint Transcript: Stifel 2025 Healthcare Conference

EyePoint Slides: FY 2025

Nov 12, 2025, 10:40 AM EST - 9 months ago

EyePoint Slides: FY 2025

EyePoint Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 10:30 AM EST - 10 months ago

EyePoint Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

EyePoint Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

EyePoint Earnings Call Transcript: Q3 2025

EyePoint Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

EyePoint Quarterly report: Q3 2025

EyePoint Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

EyePoint Earnings release: Q3 2025

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Nov 5, 2025, 7:00 AM EST - 10 months ago

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 10 months ago

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 11 months ago

EyePoint Announces Pricing of Public Offering

EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 11 months ago

EyePoint Announces Proposed Public Offering of Common Stock

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

Oct 14, 2025, 4:01 PM EDT - 11 months ago

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

EyePoint Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:45 PM EDT - 1 year ago

EyePoint Transcript: Cantor Global Healthcare Conference 2025

EyePoint Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 2:30 PM EDT - 1 year ago

EyePoint Transcript: Citi's Biopharma Back to School Conference

EyePoint Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 10:00 AM EDT - 1 year ago

EyePoint Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

EyePoint Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q2 2025

EyePoint Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q2 2025

EyePoint Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q2 2025

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:30 AM EDT - 1 year ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Aug 6, 2025, 7:00 AM EDT - 1 year ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Jul 29, 2025, 7:00 AM EDT - 1 year ago

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 2:40 PM EDT - 1 year ago

EyePoint Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

EyePoint Slides: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 2:40 PM EDT - 1 year ago

EyePoint Slides: Goldman Sachs 46th Annual Global Healthcare Conference

EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 8:30 AM EDT - 1 year ago

EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

EyePoint Slides: Investor Presentation

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Slides: Investor Presentation

EyePoint Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 10:00 AM EDT - 1 year ago

EyePoint Transcript: RBC Capital Markets Global Healthcare Conference 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing

EyePoint Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q1 2025

EyePoint Quarterly report: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q1 2025

EyePoint Earnings release: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q1 2025

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

May 7, 2025, 7:00 AM EDT - 1 year ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing

EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing

EyePoint Transcript: RBC Inaugural Virtual Ophthalmology Conference

Apr 4, 2025, 10:00 AM EDT - 1 year ago

EyePoint Transcript: RBC Inaugural Virtual Ophthalmology Conference

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

EyePoint Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 3:00 PM EDT - 1 year ago

EyePoint Transcript: Barclays 27th Annual Global Healthcare Conference

EyePoint Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 4:20 PM EDT - 1 year ago

EyePoint Transcript: Leerink’s Global Healthcare Conference 2025

EyePoint Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings Call Transcript: Q4 2024

EyePoint Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Annual report: Q4 2024

EyePoint Earnings release: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings release: Q4 2024

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Mar 5, 2025, 7:00 AM EST - 1 year ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

EyePoint Transcript: TD Cowen 45th Annual Healthcare Conference

EyePoint Slides: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

EyePoint Slides: TD Cowen 45th Annual Healthcare Conference

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

Feb 26, 2025, 7:00 AM EST - 1 year ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

EyePoint Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 9:30 AM EST - 1 year ago

EyePoint Transcript: Guggenheim SMID Cap Biotech Conference

EyePoint Transcript: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Transcript: Status Update

EyePoint Press release: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Press release: Status Update

EyePoint Slides: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Slides: Status Update

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

EyePoint Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

EyePoint Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

EyePoint Slides: FY 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

EyePoint Slides: FY 2025

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Jan 8, 2025, 7:00 AM EST - 1 year ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Dec 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 3:00 AM EST - 1 year ago

EyePoint Transcript: Jefferies London Healthcare Conference 2024

EyePoint Transcript: UBS Global Healthcare Conference 2024

Nov 13, 2024, 4:15 PM EST - 1 year ago

EyePoint Transcript: UBS Global Healthcare Conference 2024

EyePoint Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

Nov 11, 2024, 2:00 PM EST - 1 year ago

EyePoint Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

EyePoint Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Quarterly report: Q3 2024

EyePoint Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Earnings release: Q3 2024

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Nov 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 31, 2024, 4:00 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 29, 2024, 9:47 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 5:14 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 28, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Oct 24, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 2:30 PM EDT - 2 years ago

EyePoint Transcript: UBS Virtual Ophthalmology Day

EyePoint Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 11:30 AM EDT - 2 years ago

EyePoint Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

EyePoint Transcript: The Baird 2024 Global Healthcare Conference

Sep 10, 2024, 4:20 PM EDT - 2 years ago

EyePoint Transcript: The Baird 2024 Global Healthcare Conference

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Sep 4, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

EyePoint Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 15, 2024, 7:00 AM EDT - 2 years ago

EyePoint Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

EyePoint Registration statement: Registration Filing

Aug 8, 2024, 8:00 AM EDT - 2 years ago

EyePoint Registration statement: Registration Filing

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Novellino
Novellino Aug. 19 at 12:20 PM
$EYPT
0 · Reply
XRProcketman
XRProcketman Aug. 19 at 11:46 AM
$EYPT
0 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 19 at 11:39 AM
$MRNA up over 60% pharmas moving $MRK 10% $EYPT RECOVERING C/0 buying $TENX bunch of sc 13g over 22 million with 37 million outstanding $KPTI still august submission of sdna is this month
1 · Reply
MesserschmittBavaria
MesserschmittBavaria Aug. 19 at 11:38 AM
$EYPT 6-8$ soon and waiting for news
0 · Reply
Novellino
Novellino Aug. 19 at 11:29 AM
$EYPT It is a gamble, as always, but Duvaryu has proven effective—currently the specific drug with the most potential—and an acquisition by Big Pharma cannot be ruled out.
0 · Reply
Hass19
Hass19 Aug. 19 at 11:25 AM
$EYPT $6+ by the end of the day today
1 · Reply
BrexitIsStupid
BrexitIsStupid Aug. 19 at 11:11 AM
$EYPT It has recovered better than I thought it would. I am still down a lot but less worried now. As long to we get a positive Phase III result in Q4, I think the story and success continues.
0 · Reply
Love_whams
Love_whams Aug. 19 at 10:13 AM
$EYPT moving nicely my main watch included $ANNA debt free & cash rich ! gas prices TTF surging away ! & $GDC is the lotto ticket play 7500 $BTC.X just confirmed in Q10 report market cap is 50x lower than it should be watch this space save this post IMO NFA all 3 will BOOM
0 · Reply
ArmyGreen4Runner
ArmyGreen4Runner Aug. 19 at 9:47 AM
$EYPT $6-$7 by EOD
1 · Reply
Jiggles
Jiggles Aug. 19 at 9:35 AM
$EYPT
0 · Reply
MarcusTran857
MarcusTran857 Aug. 19 at 9:04 AM
$SEDG $MARA $DPZ $EYPT SolarEdge remains sensitive to solar-market recovery and margins, Marathon Digital benefits from Bitcoin prices and mining economics, Domino's benefits from delivery and franchise demand, and EYPT remains speculative. I'm watching solar installations, Bitcoin prices, restaurant sales, and liquidity.
0 · Reply
cantln
cantln Aug. 19 at 8:44 AM
$EYPT
0 · Reply
Dulge_Gappana
Dulge_Gappana Aug. 19 at 6:19 AM
$EYPT still here. PT $20 ++ most likely next p3 data read is awesome.
1 · Reply
Poet5
Poet5 Aug. 19 at 1:38 AM
$EYPT At least someone is slightly more reasonable then the reflexive idiots like Goldman and Chardan who lower it from 40.00 to 5.00. LOL. Citigroup has it at 17.00
1 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 19 at 1:11 AM
$TENX could start moving up like $EYPT LOVE EM BOTH Millenium management llc Another sc 13g for 5% FILED TODAY https://www.otcmarkets.com/filing/html?id=19713408&guid=w3UXkaUf2kq0h3h
0 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 19 at 12:48 AM
$EYPT tomorrow should be explosive l!!
1 · Reply
Novellino
Novellino Aug. 18 at 11:19 PM
$EYPT
1 · Reply
Bulletproof99
Bulletproof99 Aug. 18 at 11:10 PM
$EYPT haven’t seen a cheap call ina while I’ll gamble. 18sep
0 · Reply
Ivorthedriver
Ivorthedriver Aug. 18 at 10:59 PM
$EYPT I don't really care about a squeeze one way or the other, but...if you REALLY want to start a squeeze...Start buying ITM or near OTM calls that expire on Friday. Any near term call like those make it almost a REQUIREMENT for the MMs to immediately buy a commensurate number of shares because they'd have to DELIVER them at Friday's close. That takes those shares out of the float for those few days...and...gives you upside exposure since you hold the calls. No MM is going to sell you those calls and sit naked for 3 days. They ain't gamblers. All the best, Ivor P.S. This was the gasoline on the fire for GME in 2022.
0 · Reply
The_Blue_Print
The_Blue_Print Aug. 18 at 10:58 PM
$EYPT might recover losses here. Not in yet tho
0 · Reply
Jayjay09h
Jayjay09h Aug. 18 at 10:40 PM
$EYPT new to this stock is it worth a buy right now or wait few more days till smoke clears? Why would board of director purchase $53,000 worth in shares today..something cooking?
2 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 18 at 10:39 PM
$EYPT 6 or 7
0 · Reply